Side-by-side · Research reference

Thymosin α-1vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED8/39 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Thymosin α-1

Vesugen

Primary target

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Thymosin α-1

Vesugen

Standard dose (HBV/HCV)

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

—

Frequency

2× weekly (Mon/Thu typical)

Not specified in available literature

Lower / starter dose

0.8 mg per injection

—

Evidence basis

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

6–12 months for chronic indications

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Sterile water for injection per vial label

—

Timing

No specific time

—

Half-life

~2 hours plasma; tissue effect days

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

Thymosin α-1

Vesugen

Injection site reaction

Erythema, mild discomfort

—

GI symptoms

Rare nausea

—

Fatigue

Common during initial weeks

—

Fever / flu-like

Mild interferon-like response possible

—

Autoimmune

Theoretical risk; caution in active autoimmune disease

—

Cancer risk

No signal — used as adjuvant in oncology

—

Pregnancy / OB

Avoid

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Vesugen

—

Relative Contraindications

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Thymosin α-1

Vesugen

1. Reconstitution

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

2× weekly, e.g. Monday + Thursday.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

27–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Thymosin α-1

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)